Anticipation in Familial Chronic Lymphocytic Leukemia  by Goldin, Lynn R. et al.
Am. J. Hum. Genet. 65:265–269, 1999
265
Letters to the Editor
Am. J. Hum. Genet. 65:265, 1999
Anticipation in Familial Chronic Lymphocytic
Leukemia
To the Editor:
The term “anticipation” in genetic diseases refers to ear-
lier age at onset and/or increased severity in successive
generations. For some neurodegenerative diseases, an-
ticipation results from expansion of unstable trinucle-
otide repeats in successive generations (La Spada 1997).
Epidemiological studies have demonstrated a significant
familial effect for leukemia (Goldgar et al. 1994) and
chronic lymphocytic leukemia (CLL) in particular (Cart-
wright et al. 1987; Linet et al. 1989). Families with mul-
tiple affected individuals are rare in population studies
but may be more common in clinical samples (Cuttner
1992). The mode of inheritance is unknown for leuke-
mia, although it has been hypothesized that in pedigrees
with multiple affecteds the disease is due to a single
autosomal dominant gene (Horwitz 1997). Evidence for
anticipation in familial leukemia has been reported by
Horwitz et al. (1996), on the basis of a literature review
of published pedigrees with acute myelogenous leukemia
(AML) and CLL. The average difference, in age of onset
of CLL, between two generations in seven pedigrees (17
individuals), was 15 years, although the mean parent-
offspring difference was 21 years. Yuille et al. (1998)
have recently confirmed this finding, in 10 families with
two generations affected with CLL (mostly parent-off-
spring pairs) systematically ascertained from a patient
registry. They found the age of onset difference between
generations to be 22 years. Given that there is a molec-
ular basis for anticipation in some diseases, it is impor-
tant to determine if there is anticipation in CLL. As with
other diseases, anticipation in CLL could be due to a
number of well-known sampling biases (reviewed by
McInnis 1996), such as the tendency to select early-onset
probands, parents with late onset, and families with si-
multaneous onset of disease in parents and offspring, or
other biases that cause a truncation of the sample of
families (Hodge and Wickramartne 1995; Fraser 1997).
Another bias particular to CLL may arise from the fact
that individuals are often diagnosed on the basis of rou-
tine blood tests when they are asymptomatic, and they
may remain asymptomatic for a number of years. It is
conceivable that an anticipation phenomenon could be
attributable to changes in medical practice over time,
such that, because of the greater routine use of clinical
tests, individuals in the younger generations are being
diagnosed earlier. Data collected by the National Cancer
Institute Surveillance, Epidemiology, and End Results
(SEER) program during the past 20 years have shown
little secular change in the incidence of CLL (SEER). In
fact, recent studies that have reported an increased in-
cidence of CLL find the increase to be limited to older
individuals (Call et al. 1994; Rozman et al. 1997). We
have been studying familial CLL for a number of years
and have analyzed age at onset in pedigrees with at least
two generations affected. We find evidence for antici-
pation in these families, even when stage at diagnosis
and other potential sampling biases are taken into
account.
Since 1974, we have ascertained and collected clinical
data on 27 families, each of which has two or more
confirmed cases of CLL (see Caporaso et al. 1991). Thir-
teen of these families have cases of CLL in two gener-
ations; the remainder have affected siblings and/or
cousins. We have complete age-at-onset data for 32
individuals from the 13 two-generation families. One
family has missing age-at-onset data on an affected par-
ent. In the majority of cases, age at onset was determined
on the basis of medical chart review, but in a few cases
we relied on personal reports. Insufficient information
was available to determine the disease stage for each
individual, by use of either the Rai or Binet staging meth-
ods (reviewed in Dighiero and Binet 1996), but, when-
ever possible, we determined whether the individual was
“symptomatic” or “asymptomatic” when diagnosed.
We classified as “symptomatic” individuals showing
signs or symptoms attributed to CLL, including lym-
phadenopathy, splenomegaly, anemia, and thrombocy-
topenia. Individuals were classified as “asymptomatic”
if they presented only with a peripheral-blood absolute
lymphocyte count (ALC) (Zwiebel and9 5.0# 10 /liter
Cheson 1998). For those individuals diagnosed asymp-
tomatically, we also noted the age at which they became
symptomatic, when this information was available in the
medical chart. Individuals were classified into two gen-
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Table 1
Age at Onset and Year of Diagnosis in 13 Families Investigated for Anticipation
Family and Relationship
to Proband Generation
Age at
Diagnosis
(years)
Symptomatic
at Diagnosis?a
Year at
Diagnosis
1:
Father 1 69 yes 1954
Proband (female) 2 47 yes 1972
Brother 2 49 no 1971
Brother 2 47 yes 1968
Sister 2 57b no 1974
2:
Father 1 75c yes 1967
Uncle 1 63c yes 1955
Proband (male) 2 56 ? 1978
3:
Uncle 1 70 ? 1960
Proband (male) 2 50 no 1977
First cousin (female) 2 52 no 1978
4:
Proband (male) 1 49 ? 1984
Nephew 2 53 ? 1988
5:
Mother 1 82 yes 1980
Proband (female) 2 64 ? 1985
6:
Father 0d 79 ? 1965
Proband (female) 1 74 no 1990
Son 2 55 yes 1991
7:
Aunt 1 58 ? 1961
Proband (male) 2 44 yes 1986
8:
Mother 1 83 no 1978
Proband (male) 2 55 yes 1983
9:
Mother 1 32 yes 1961
Proband (female) 2 37 yes 1993
Brother 2 42b yes 1995
10:
Mother 1 58 ? 1965
Proband (female) 2 52 ? 1991
11:
Father 1 76 no 1997
Proband (male) 2 51 no 1997
12:
Uncle 1 77 ? 1984
Proband (male) 2 65 no 1996
Brother 2 50 no 1994
13:
Mother 1 ? ? ?
Proband (female) 2 35 yes 1990
a A question mark (?) indicates that data were not available.
b Individual sought diagnosis because of family history.
c Age at diagnosis is age at death.
d Not included in analysis.
erations, on the basis of their position in the pedigree.
Generation 2 was defined as the youngest generation
affected; the generation preceding them was considered
to be generation 1. All affected individuals in each family
were included in the analysis. There was one family with
three generations affected; the individual in the oldest
generation was not included in the analysis. The age-at-
onset data for all individuals are displayed in table 1.
In 11 of the 13 families, the proband was in the younger
generation.
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Figure 1 Age at onset of CLL, in two generations
We found that the average age at onset in generation
1 is 66.7 years (SD 14.6) and that that in generation 2
is 50.7 (SD 7.8). These onset ages are similar to those
reported by Horwitz et al. (1996). We used survival anal-
ysis to plot the age-at-onset distribution for each gen-
eration, using the Kaplan-Meier method as implemented
in the SAS Lifetest procedure (Allison 1995). The results
are displayed in figure 1. The difference between the two
generations is highly significant, whether based on the
log-rank test ( ) or the Wilcoxon test (P  .0001 P 
)..0009
We examined the generational differences after taking
into account a number of possible biases. In this small
sample, there were no significant age-at-onset differences
between males and females, and each generation had an
approximately equal proportion of males and females.
We scored the individuals for whether they were symp-
tomatic, asymptomatic, or unknown at diagnosis. The
proportion of symptomatic individuals did not differ by
generation (5/13 [.38] in generation 1 and 8/19 [.42] in
generation 2; see table 1). In addition—after family 9,
in which all members had unusually early ages at onset,
was excluded—there was no difference, between symp-
tomatic and asymptomatic individuals. There were two
individuals in the sample who sought diagnosis because
of their family history. These two individuals, indicated
in table 1, had ages at onset of 57 and 42 years, so
eliminating them would not change the findings. In order
to analyze our data in the most conservative way pos-
sible, we increased the age at onset for five individuals
(generation 2) who were asymptomatic at diagnosis but
whose age at onset of clinical symptoms could be de-
termined. In addition, there were two individuals from
generation 1 who were diagnosed on the basis of death
certificates and who were assigned onset ages equal to
their ages at death. We lowered these individuals’ ages
at onset by 7 years, since this is the median time between
age at onset of symptoms and death (Zwiebel and Che-
son 1998). Even under these conservative assumptions,
the age at onset in the second generation was signifi-
cantly lower than that in the first generation (log-rank
test ). It should also be noted that, evenP  .0002
though we did not analyze all three generations in the
three-generation family, the proband’s father (generation
0) had a later age at onset than did either the proband
or her son. We also considered the possible bias due to
preferential ascertainment of families with simultaneous
onset in two generations. In 5 of 12 families for which
complete data were available, individuals in both gen-
erations were diagnosed within a 5-year period (table
1). In the seven other families, the average difference, in
calendar year of diagnosis, between generations was 21
years, and the average difference, in age at onset, be-
tween generations was 13 years. Thus, our finding of
anticipation is not being driven by the presence of fam-
ilies with simultaneous onset in two generations.
We find that, between the two generations in the fam-
ilies we studied, the average decrease in age at onset of
CLL was 16 years. One could argue that we have pref-
erentially ascertained early-onset probands. The average
age at onset in all 27 of the families that we studied is
54.9 years for probands only and 59.6 years for all
affecteds. The average age at onset of CLL has been
reported to be ∼70 in some population-based samples
(Travis et al. 1992; Hjalmar et al. 1996) but ∼62–65 in
other studies (Radovanic et al. 1994; Rozman et al.
1997). Thus, probands from the multiplex families that
we studied have a somewhat decreased age at onset,
compared with that in cases from the population. How-
ever, for this analysis, we included all affected individuals
in a family, which decreases any effect due to earlier
onset in the index case. We cannot completely rule out
the possibility that anticipation in these families is due
to a cohort effect, since, in all of the families that we
studied, birth cohort is confounded with generation. As
is to be expected from the way in which pedigrees are
usually ascertained in genetic studies, the second gen-
eration of individuals are from cohorts born more re-
cently than those of the first generation. However, a
cohort effect seems unlikely, given the lack of secular
trends in CLL, as mentioned above. The age at onset of
CLL is also sufficiently late in life that it would not affect
fertility, and we are not likely to have missed families
with early onset in parents and later onset in offspring.
Horwitz et al. (1996) suggested that the very large dif-
ference (21 years) that they found between parents and
offspring in published families was also consistent with
the effect of some common environmental exposure.
There is no well-established environmental risk factor
for CLL, although susceptibility to some environmental
risk factor might exist in subjects with some unidentified
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genetic susceptibility factor. Although we cannot rule out
such an effect, we find a substantial but smaller age-at-
onset decrease between generations. We also find the
decrease to be present in families that are not correlated
for year of diagnosis, arguing against a purely environ-
mental explanation.
In conclusion, we report significant evidence for an-
ticipation in familial CLL and have ruled out various
biases that could account for the finding. Therefore, we
plan to look for expanded trinucleotide repeats in can-
didate genes in families showing anticipation.
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